Allogeneic cord blood–derived NK cells engineered to express a CD70-specific chimeric antigen receptor and an IL-15 transgene. The CAR redirects NK cells to CD70-expressing tumor cells to trigger antigen-specific NK activation and cytotoxicity (perforin/granzyme release and death receptor pathways), while IL-15 provides autocrine support for survival, proliferation, and persistence in vivo.